$HSIC

Albertini Andrea sold (to issuer) 3,984 shares of HSIC

Albertini Andrea (CEO, Global Dist. & Tech.) sold (to issuer) 3,984 shares of HENRY SCHEIN INC (HSIC) on 2026-09-08.

Original reporting
SEC EDGAR · Albertini Andrea
Published Sep 9, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HSIC
Neutral
high confidence
Mentioned
$HSIC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HSICNeutralLow
01

Why it matters

The sale represents a modest reduction in the CEO's stake, but given the small size, it likely has minimal impact on investor perception.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

No 10b5‑1 plan and lack of price disclosure limit insight into motive.

Relevance 4/10Novelty 4/10Timing: Filed on 2026-09-09, transaction dated 2026-09-08

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$HSICNeutralHigh confidence
Context

CEO Andrea Albertini sold 3,984 shares of Henry Schein Inc. via a Form 4 filing on 2026-09-08.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is small relative to total holdings and market cap; no 10b5-1 plan and no disclosed price.

Market effects

None; Henry Schein operates in health‑care distribution, but the insider sale is too small to affect sector sentiment.

None; the company is US‑based with no broader regional effect.

None

Counterpoint

If the CEO is reducing exposure, it could signal concerns about future performance.

Key entities

  • Henry Schein Inc.

    Healthcare products and services distributor.

  • Andrea Albertini

    CEO of Henry Schein.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HSICMed

HSIC: Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance

Henry Schein, Inc. [HSIC] outlined plans to accelerate growth, simplify operations, and improve operating income by $200 million, targeting double-digit EPS growth. The company highlighted strong performance in dental and medical segments, focusing on consumables, private label, and technology. Leadership emphasized disciplined M&A and share buybacks for capital allocation.

$HSICMed

Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

Henry Schein, Inc. (HSIC) reported broad-based growth in Q2, with sales increases across distribution, specialty products, and technology. Management raised its 2026 sales and earnings guidance. HSIC trades at a discount to market benchmarks but faces risks from leverage and execution challenges. The company aims for $200M in operating income improvement by 2026, with savings initiatives underway.

$HSICMedAI 8/10

Henry Schein (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.

$HSICMed

Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution

Henry Schein Inc. outlined a transformation focused on AI, simpler leadership, and faster execution in its first earnings report under CEO Fred Lowery. The company reported Q2 net sales of $3.46B (+6.7%) and net income of $94M (+9.3%), raised its 2026 sales outlook to 4.5% to 5.5%, and announced a leadership reorganization integrating supply chain and distribution. It targets $200M+ operating improvements.

$HSICMedAI 8/10

Henry Schein, Inc. Q2 2026 Earnings Call Summary

Henry Schein reported Q2 2026 progress including faster internal local-currency sales growth, driven by dental merchandise market-share gains and higher technology platform share. The company raised full-year 2026 sales growth guidance to 4.5% to 5.5% and expects $125 million operating income improvement run rate by end-2026. Restructuring expenses were $29 million.